| ￥3500 | |
| Z05516-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
>?95%?as?determined?by?Bis?Tris?PAGE? >?95%?as?determined?by?HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized IL-8/CXCL8, His, Human at 1μg/ml (100μl/well) on the plate can bind Anti?IL?8 Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 9.5 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 11-13 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.Several promising approaches that target directly or indirectly IL-8 effects in gliomas are currently in progress while more-in-depth studies are needed to validate its biomarker role and elucidate the underlying molecular mechanisms. |
| Synonyms | Interleukin-8; IL-8; GCP-1; MDNCF; MONAP; NAP-1; GCP/IL-8 protein IV; IL8/NAP1 form I; CXCL8; LECT; LUCT; LYNAP; NAF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
